03/23/2026
Researchers, including our own Drs. Jonna Westover and Brian Gowen, have uncovered new insights into how human antibodies recognize and neutralize Rift Valley fever virus (RVFV), a pathogen that threatens both human and animal health. 🦠🔬
By comparing two protective monoclonal antibodies, RVFV‑268 and RVFV‑379, the team found that RVFV‑379 binds the virus with a larger footprint and at a unique angle, yet shows limited neutralization across RVFV strains due to natural variation in its target region. These findings deepen our understanding of antibody–virus interactions and help guide the development of future vaccines capable of providing broader, more effective protection. 💉✨
Read more: https://pubmed.ncbi.nlm.nih.gov/41701720/
Rift Valley fever virus (RVFV) poses a continued threat to human health and animal husbandry. Two neutralizing and protective human monoclonal antibodies (mAbs), RVFV-268 and RVFV-379, exhibit similar affinities and epitope footprints on the Gn glycoprotein component of the RVFV Gn-Gc capsomeric lat...